Cognition Therapeutics Inc (CGTX)

03:40 AM

What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia

03:40 AM

03:41 AM

Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional

03:41 AM

Jul 23, 2025

What analysts say about Cognition Therapeutics Inc. stockFree Bull & Bear Market Updates - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Cognition Therapeutics Inc. a good long term investmentFree Predictions - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times

Jul 21, 2025

Jul 21, 2025

Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan

Jul 21, 2025

Jul 19, 2025

How high can Cognition Therapeutics Inc. stock price go in 2025Capital Efficient Investment Tips - beatles.ru

Jul 19, 2025

Jul 17, 2025

Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire

Jul 17, 2025

Jul 16, 2025

Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics stock soars after DLB study results - Investing.com

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com Nigeria

Jul 16, 2025

Jul 16, 2025

CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire

Jul 16, 2025

Jul 16, 2025

Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan

Jul 16, 2025

Jul 16, 2025

Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com

Jul 16, 2025

Jul 15, 2025

How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser

Jul 15, 2025

Jul 15, 2025

Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser

Jul 15, 2025

Jul 15, 2025

What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser

Jul 15, 2025

Jul 15, 2025

Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest

Jul 15, 2025

Jul 14, 2025

CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com

Jul 14, 2025

Jul 12, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 12, 2025

Jul 12, 2025

Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World

Jul 12, 2025